Targets › SCN
2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 2; Other.
Open in Phaseline: the race on SCN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National University Hospital, Singapore | Prilocaine Sodium channel blocker (local anesthetic) | SCN | Phase 4 | Knee Replacement, Total | – |
| University of British Columbia | ST-01 Sustained release lidocaine (70 mg/mL); local anesthetic inhibiting sodium channels | SCN | Phase 2 | Postoperative Pain | – |
Knee Replacement, Total (1) Postoperative Pain (1)
small molecule (2)
National University Hospital, Singapore (1) University of British Columbia (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.